3 Dividend Stocks That Are Screaming Buys in November

Core Viewpoint - Political uncertainty has created buying opportunities among blue-chip healthcare stocks with significant dividends, particularly due to the nomination of Robert F. Kennedy Jr. as Secretary of Health and Human Services, which has introduced volatility in the healthcare sector [1][2]. Group 1: AbbVie - AbbVie shares are down over 18% from their high, influenced by political factors and the $8.7 billion acquisition of Cerevel, which faced setbacks with its schizophrenia drug emraclidine failing clinical trials [3][4]. - Despite the challenges, AbbVie remains a well-diversified company with a solid dividend yield of 3.7% and a payout ratio of 56% of estimated 2024 earnings, indicating financial stability [4][5]. - The stock trades at a forward P/E ratio of 15, with analysts projecting earnings growth of 8% to 9% annually, presenting an opportunity for investors to achieve total returns averaging 11% to 13% annually [5]. Group 2: Pfizer - Pfizer's stock has been negatively impacted by declining earnings and industry sentiment, trading at less than 9 times earnings, with a dividend yield of 6.7%, the highest since the financial crisis [6][7]. - The company's dividend payout ratio is only 58% of its 2024 earnings estimates, and Pfizer is shifting focus to oncology, with expected earnings growth of 10% to 11% annually over the next three to five years [7][8]. - Pfizer presents a high-yield dividend stock at a bargain price, with management committed to supporting and increasing the dividend, making it a contrarian investment opportunity [8]. Group 3: Johnson & Johnson - Johnson & Johnson's stock has declined 18% from its high, trading at 15 times 2024 earnings estimates, amid ongoing talcum powder litigation that could incur significant costs [9][10]. - The company maintains strong fundamentals with over $20 billion in cash, and any settlements are expected to be paid over many years, indicating resilience [10][11]. - Analysts forecast earnings growth of 5% to 6% annually, with a modest 50% payout ratio based on 2024 earnings estimates, providing a generous 3.2% yield and a growing dividend [11].